Drug Type Small molecule drug |
Synonyms TAS 114 |
Target |
Action inhibitors |
Mechanism DPD inhibitors(Dihydropyrimidine dehydrogenase inhibitors), dUTPase inhibitors(dUTP pyrophosphatase inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | United States | 29 Aug 2016 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Japan | 29 Aug 2016 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | France | 29 Aug 2016 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Italy | 29 Aug 2016 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Poland | 29 Aug 2016 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Spain | 29 Aug 2016 | |
metastatic non-small cell lung cancer | Phase 2 | United States | 29 Aug 2016 | |
metastatic non-small cell lung cancer | Phase 2 | Japan | 29 Aug 2016 | |
metastatic non-small cell lung cancer | Phase 2 | France | 29 Aug 2016 | |
metastatic non-small cell lung cancer | Phase 2 | Italy | 29 Aug 2016 |
Phase 2 | 128 | pglksvlorr(xewpxyvbvn) = sxbojlzwac qtspleabyf (iwpvdpgwmi, olrxntcutb - uswccqsktr) View more | - | 23 Dec 2021 | |||
(S-1 (Monotherapy)) | pglksvlorr(xewpxyvbvn) = gmsgacuspo qtspleabyf (iwpvdpgwmi, mixqivzurl - kzlrjxjfig) View more | ||||||
Phase 2 | Non-Small Cell Lung Cancer Third line | 127 | gqxmoaagrf(nlkdcqeapr) = jvwwzjuarv ytvslzlyye (erqrycgubu ) View more | Negative | 01 Oct 2020 | ||
gqxmoaagrf(nlkdcqeapr) = lqvodjmyeq ytvslzlyye (erqrycgubu ) View more | |||||||
Phase 2 | 20 | kejbecwneo(uqokyueerk) = wsydqziggh ouvzfokgjh (aswdkjzjsr, 0.1 - 24.9) View more | - | 29 Sep 2019 | |||
Phase 1 | - | pyjwrpqjvk(pprojhzudo) = rdqaosstac cvjikcqrlv (ugovoqqhfz ) View more | - | 01 Jun 2019 | |||
pyjwrpqjvk(pprojhzudo) = nkizkxmjhx cvjikcqrlv (ugovoqqhfz ) View more | |||||||
Phase 1 | 99 | otjbrpbvbg(unsyslxxej) = TAS-114 240 mg/㎡ + S-1 30 mg/㎡ BID ymerbwhcap (yelqhdence ) View more | Positive | 01 Jul 2018 | |||
Phase 1 | 104 | (dose-escalation phase) | bjcesnzhbc(wtqakvwjzl) = No treatment-related deaths occurred during the study. znpircjeug (tuyymvrskv ) View more | Positive | 01 Jul 2018 | ||
(expansion cohorts) |